ArticleBlood advances2024

Measurable residual disease monitoring in AML with FLT3-ITD treated with intensive chemotherapy plus midostaurin.

Frank G Rücker et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.